NCT07436390 2026-03-02
MAK
Institute of Oncology Ljubljana
Phase NA Completed
Clinical Trials
13 trialsNCT07422779 2026-02-20
MAK
Institute of Oncology Ljubljana
Phase NA Recruiting
NCT04603248 2026-02-12
A Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Yonsei University
Phase NA Active not recruiting
NCT05533983 2025-12-03
NIVO-FMT
Asan Medical Center
Phase NA Recruiting
NCT07233668 2025-12-03
IVE in mRCC
Seoul National University Hospital
Phase NA Not yet recruiting
NCT06519682 2025-08-29
A Pilot Study Investigating Upfront Adaptive Immunotherapy Approach in Children, Adolescent and Young Adult (CAYA) Patients With Replication-Repair Deficient (RRD) High-Grade Gliomas (HGG)
The Hospital for Sick Children
Phase NA Recruiting
NCT07053202 2025-07-08
TACE With Immune Agents for Angiogenesis in Hepatocellular Carcinoma
The First Hospital of Hebei Medical University
Phase NA Completed
NCT05652673 2025-02-28
Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial
Erasmus Medical Center
Phase NA Recruiting
NCT04256213 2024-12-12
COLIBRI
ARCAGY/ GINECO GROUP
Phase NA Completed
NCT02833233 2024-10-23
A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT05745233 2023-08-24
Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites
China Medical University Hospital
Phase NA Enrolling by invitation
NCT04801966 2023-05-10
TAILOR
Peter MacCallum Cancer Centre, Australia
Phase NA Terminated
NCT05233358 2022-02-10
HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure
The Central Hospital of Lishui City
Phase NA Unknown